HITE Hedge Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

HITE Hedge Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-798	Closed	-$267K	–	99
2022 Q1	$267K	Sell	798 -227	-22%	-$65.8K	0.03%	138
2021 Q4	$333K	Hold	1,025	–	–	0.04%	141
2021 Q3	$498K	Hold	1,025	–	–	0.06%	127
2021 Q2	$476K	Buy	+1,025	New	+$559K	0.07%	124

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HITE Hedge Asset Management's BTAI Position: Q2 2022 in Review

HITE Hedge Asset Management sold out of BioXcel Therapeutics (BTAI) in Q2 2022, closing a stake of 798 shares — an estimated $267K sold.

HITE Hedge Asset Management first reported a position in BTAI in Q2 2021 and held it in 4 quarters. The position peaked at $498K in Q3 2021. 94 funds tracked by Wall St. Rank hold BTAI as of Q2 2022.

HITE Hedge Asset Management reported no remaining BioXcel Therapeutics position as of Q2 2022 after selling out during the quarter.
HITE Hedge Asset Management sold 798 BioXcel Therapeutics shares in Q2 2022, an estimated $267K.
HITE Hedge Asset Management first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 4 quarters.
HITE Hedge Asset Management's BioXcel Therapeutics position peaked at $498K in Q3 2021.
94 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2022.

Based on HITE Hedge Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.